This book helps readers integrate *in silico*, *in vitro*, and *in vivo* ADMET (absorption, distribution, metabolism, elimination and toxicity) and PK (pharmacokinetics) data with routine testing applications so that pharmaceutical scientists can diagnose ADMET problems and present appropriate recommendations to move drug discovery programs forward.

The book introduces the current clinical practice for drug discovery and development along with the impact on early risk assessment; consolidates the tools and models to intelligently integrate existing *in silico*, *in vitro* and *in vivo* ADMET data; and demonstrates successful cases and lessons learned from real drug discovery and development. In short, it is a book aimed to provide a practical road map for drug discovery and development scientists to generate efficacious and safe drugs for unmet medical needs.

**ABOUT THE AUTHOR**

**Jianling Wang** is the Cambridge Head of Discovery ADME at Novartis Institutes for BioMedical Research. He has published over 40 journal papers, reviews, and book chapters and lectured at over 30 scientific conferences and courses.

**Laszlo Urban** is the Executive Director for Preclinical Safety Profiling at Novartis Institutes for BioMedical Research. He has over 10 years of experience in academia and 20 years in the pharmaceutical industry. Among Dr. Urban’s publications are
over 120 peer-reviewed scientific papers, 3 books including *Hit and Lead Profiling: Identification and Optimization of Drug-like Molecules* (Wiley, 2009).

For additional product details, please visit https://www.wiley.com/en-us